ONC-T NR today 36m at 5.00
Oncolytics receives patent No. 2,415,750
2006-04-11 05:23 ET - News Release
Ms. Cathy Ward reports
ONCOLYTICS BIOTECH INC. ANNOUNCES ISSUANCE OF 5TH CANADIAN PATENT
Oncolytics Biotech Inc. has been granted Canadian patent 2,415,750, entitled, "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." The claims describe methods for preventing reovirus recognition by the host immune system, while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells.
"The claims in this Canadian patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "Oncolytics has secured patent protection for this new treatment modality in the United States, and we are pleased to add this protection to our Canadian patent portfolio."
We seek Safe Harbor.
